Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib + Pembrolizumab in First-Line Maintenance for Metastatic Squamous NSCLC
NCT07845786Phase 2Not yet recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Dec 2026
- Primary completion
- Jun 2028
01
Overview
Phase 2, open-label, single-arm trial of zanzalintinib in squamous cell carcinoma of the lung (SCCL), sponsored by Exelixis, Inc. Primary endpoint: Progression-Free Survival at 6 Months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
zanzalintinib
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT07845786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07845786.